

November 24, 2020

The beginning of the pandemic's end?

We are increasingly confident in our constructive base case for the world economy in 2021 and beyond, but plenty of question marks remain.

- _ Learning to cope with the virus was always likely to be an uneven process, but there are signs of progress.
- _ So far, there are few signs of permanent economic scarring one might expect from such a sharp contraction.
- _ The economic rebound of recent months hints at a bright future ahead, once lockdown measures are fully lifted.



Johannes Müller
Head of Macro Research

We are increasingly confident in our constructive base case for the world economy in 2021 and beyond. In part, that reflects recent economic data. Around the world, the economic recovery after the collapse in spring has been quite impressive. This shows a few things, notably that at least so far, there are few signs of permanent economic scarring one might expect from such a sharp contraction. It is becoming increasingly clear that there are now several ways of how daily life might return to something close to the pre-pandemic normal. These paths are no longer just potentially feasible but also increasingly visible. That is more than could have been said with much confidence three months ago.

Based on the experience of coronaviruses causing the common cold, getting quickly towards first-generation vaccines that might work was not a given.¹ Given the vast resources deployed we hoped for as much, and had already included some relief over the course of 2021 into our forecasts. Set against this are the renewed, if somewhat more targeted, lockdown measures during the winter months in most of the Northern Hemisphere. Learning to cope with the virus was always likely to be an uneven process, but there are signs of progress. Alternative, quicker testing solutions have become

available. Trends for therapeutics appear encouraging. As with vaccines, there is, of course, still the potential for plenty of setbacks, not least in terms of how quickly policymakers will prove able to use them well.

Policymaking is one of the reasons why many question marks remain. With the U.S. elections finally behind us, the likely outcome of a Biden administration with a Republican Senate has not significantly changed our forecasts. While there is a risk of fiscal-policy paralysis, the downside risk to economic forecasts is partly offset by the evidence so far that the U.S. economy has proved flexible enough to bounce back even as infection rates continued to rise. The picture is murkier in Europe. Still, the two-stage recovery we forecast this spring has, if anything, underestimated the initial strength of economic momentum somewhat. From now onward, we have penciled in a softening of momentum. We expect many of the measures to contain the virus to remain for months, not weeks. That said, we do not expect a broad third or fourth wave of nationwide lockdowns. We believe this strengthens the prospects of a year 2021 with above-potential growth, and even growth in 2022 could be decent. In our view, inflation should not be an issue of 2020 nor 2021.

¹ <https://www.nature.com/articles/d41586-020-02400-7>

With gloomy headlines on the rise again now, all this might sound a bit too good to be true, by the time you read this. We would certainly not wish to downplay the role of sentiment effects, merely suggest that in another three months, the headlines and the sentiment might already be very different. In his book "Narrative Economics," the economist Robert Shiller describes how perceptions and the stories we tell each other can drive economic events.² Some of his most striking and timely examples concern "the 1918 flu pandemic, often called the Spanish flu, [which] cost more lives than World War I" (p.108). Prior to Covid-19, the period from 1920 to 1921 was "the sharpest depression (meaning the fastest decline and recovery) in U.S. history since the advent of modern statistics," Shiller writes (p. 242). In marked contrast to perceptions of the Great Depression a decade later, this "Forgotten Depression" was swiftly followed by a sharp recovery, starting in 1921. It was seen as "a transitional phase back to normalcy after a war and an influenza epidemic," Shiller concludes (p. 252).

What to make of any such historic analogy? Clearly, not too much at the outset of a once-in-100-years crisis. As far as the U.S. is concerned, that "Forgotten Depression" of 1920 constituted a sample size of one – not enough, as any first-year undergraduate of statistics will know, to draw meaningful inferences from. The picture becomes quite bleak, once the experience of other industrialized countries during the 1920s is considered alongside the economic boom in the U.S. (where it soon came known as "The Roaring 20s," as chronicled by F. Scott Fitzgerald in "The Great Gatsby").

Clearly, a lot has changed since then but not, perhaps, the capacity of economic commentators to be led astray by the most recent data or the moment's most compelling narrative. The economic rebound of recent months hints at a bright

future ahead, once lockdown measures are fully lifted – "a transitional phase back to normalcy," to use Shiller's wording. Still, we would warn readers not to place too much reliance on any particular bit of news, whether it appears positive or negative. It is far too early to say whether any of the first generation of vaccines will offer sterilizing immunity – that is prevent those vaccinated not just from getting sick but also from spreading the virus.³ Worse still, as Nassim Taleb pointed out 15 years ago, investors are not the only ones to be frequently "Fooled by Randomness."⁴ When it comes to complicated scientific matters such as late-stage clinical trials, journalists and especially their headline writers may sometimes make pretty elementary mistakes. A perennial favorite is to confuse the absence of evidence with the evidence of absence.

Early results of the first large-scale vaccine trials were widely touted with eye-catching headlines. However, these were interim and partial results, released via press release. The data had been collected a mere seven days after the second dose was administered. It revealed 94 symptomatic cases, of which 86 appear to have been in the group that had been given the placebo instead of the vaccine.⁵ The next release suggested that effectiveness might be even higher than initially thought, as did data from a competing vaccine also under development.⁶ Rather than focusing on the specific percentages and small changes in how high effectiveness seem in any particular cohort, this should serve as a reminder of the role randomness necessarily plays in such trials. Pharmaceutical companies structure their trials so as to extract as much information as possible from early data. Still, we believe it will take quite a bit of time, and a lot more data, to see whether any one particular vaccine will prove both safe and "highly effective." Let alone mark a decisive turning point in the fight against Covid-19.⁷

² Shiller, R. (2019) "Narrative Economics: How Stories Go Viral and Drive Major Economic," Princeton University Press

³ <https://www.statnews.com/2020/08/25/four-scenarios-on-how-we-might-develop-immunity-to-covid-19/>

⁴ Nassim Nicholas Taleb (2004), "Fooled by Randomness: The Hidden Role of Chance in Life and in the Markets," 2nd edition, Thomson Texere.

⁵ <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against>

⁶ <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine> and <https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy>

⁷ See, for example, the overview of recent vaccine developments in:

<https://www.economist.com/briefing/2020/11/14/an-effective-covid-19-vaccine-is-a-turning-point-in-the-pandemic>

GLOSSARY

Fiscal policy describes government spending policies that influence macroeconomic conditions. Through fiscal policy, the government attempts to improve unemployment rates, control inflation, stabilize business cycles and influence interest rates in an effort to control the economy.

The **Great Depression** was the deepest and longest-lasting economic downturn in the history of the Western industrialized world.

The **Republican Party (Republicans)**, also referred to as Grand Old Party (GOP), is one of the two major political parties in the United States. It is generally to the right of its main rival, the Democratic Party.

The **United States Senate** is a legislative chamber consisting of 100 Senators, with each state being represented by two Senators. Senators are elected for six year, overlapping terms in their respective state.

Important Information

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries, such as DWS Distributors, Inc., which offers investment products, or DWS Investment Management Americas Inc. and RREEF America L.L.C., which offer advisory services.

This document has been prepared without consideration of the investment needs, objectives or financial circumstances of any investor. Before making an investment decision, investors need to consider, with or without the assistance of an investment adviser, whether the investments and strategies described or provided by Deutsche Bank, are appropriate, in light of their particular investment needs, objectives and financial circumstances. Furthermore, this document is for information/discussion purposes only and does not and is not intended to constitute an offer, recommendation or solicitation to conclude a transaction or the basis for any contract to purchase or sell any security, or other instrument, or for Deutsche Bank to enter into or arrange any type of transaction as a consequence of any information contained herein and should not be treated as giving investment advice. Deutsche Bank AG, including its subsidiaries and affiliates, does not provide legal, tax or accounting advice. This communication was prepared solely in connection with the promotion or marketing, to the extent permitted by applicable law, of the transaction or matter addressed herein, and was not intended or written to be used, and cannot be relied upon, by any taxpayer for the purposes of avoiding any U.S. federal tax penalties. The recipient of this communication should seek advice from an independent tax advisor regarding any tax matters addressed herein based on its particular circumstances. Investments with Deutsche Bank are not guaranteed, unless specified. Although information in this document has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness, and it should not be relied upon as such. All opinions and estimates herein, including forecast returns, reflect our judgment on the date of this report, are subject to change without notice and involve a number of assumptions which may not prove valid.

Investments are subject to various risks, including market fluctuations, regulatory change, counterparty risk, possible delays in repayment and loss of income and principal invested. The value of investments can fall as well as rise and you may not recover the amount originally invested at any point in time. Furthermore, substantial fluctuations of the value of the investment are possible even over short periods of time. Further, investment in international markets can be affected by a host of factors, including political or social conditions, diplomatic relations, limitations or removal of funds or assets or imposition of (or change in) exchange control or tax regulations in such markets. Additionally, investments denominated in an alternative currency will be subject to currency risk, changes in exchange rates which may have an adverse effect on the value, price or income of the investment. This document does not identify all the risks (direct and indirect) or other considerations which might be material to you when entering into a transaction. The terms of an investment may be exclusively subject to the detailed provisions, including risk considerations, contained in the Offering Documents. When making an investment decision, you should rely on the final documentation relating to the investment and not the summary contained in this document.

This publication contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. The forward looking statements expressed constitute the author's judgment as of the date of this material. Forward looking statements involve significant elements of subjective judgments and analyses and changes thereto and/or consideration of different or additional factors could have a material impact on the results indicated. Therefore, actual results may vary, perhaps materially, from the results contained herein. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statements or to any other financial information contained herein. We assume no responsibility to advise the recipients of this document with regard to changes in our views.

No assurance can be given that any investment described herein would yield favorable investment results or that the investment objectives will be achieved. Any securities or financial instruments presented herein are not insured by the Federal Deposit Insurance Corporation ("FDIC") unless specifically noted, and are not guaranteed by or obligations of Deutsche Bank AG or its affiliates. We or our affiliates or persons associated with us may act upon or use material in this report prior to publication. DB may engage in transactions in a manner inconsistent with the views discussed herein. Opinions expressed herein may differ from the opinions expressed by departments or other divisions or affiliates of Deutsche Bank. This document may not be reproduced or circulated without our written authority. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Deutsche Bank to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions.

Past performance is no guarantee of future results; nothing contained herein shall constitute any representation or warranty as to future performance. Further information is available upon investor's request. All third party data (such as MSCI, S&P & Bloomberg) are copyrighted by and proprietary to the provider.

Deutsche Bank AG is authorised under German Banking Law (competent authority: European Central Bank and the BaFin, Germany's Federal Financial Supervisory Authority) and by the Prudential Regulation Authority and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority. Details about the extent of our authorisation and regulation by the Prudential Regulation Authority, and regulation by the Financial Conduct Authority are available from us on request.

For investors in Bermuda: This is not an offering of securities or interests in any product. Such securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.

© 2020 DWS Investment GmbH, Mainzer Landstraße 11-17, 60329 Frankfurt am Main, Germany. All rights reserved.

R-079809-1 (11/20)